7 research outputs found
Consent-Based Humanitarian Intervention: Giving Sovereign Responsibility Back to the Sovereign
The repeated failure of the United Nations Charter regime to respond to humanitarian crises— and to prevent interventions outside the regime—has laid bare a conflict that lies at the heart of modern international law. This failure has revealed that the twin commitments on which the post-World War II international legal system has been built— sovereign rights and sovereign responsibilities— are often deeply at odds. The response of scholars to this tension has often been to choose sides in the fight. Scholars who place greater value on human rights than state sovereignty have sought to craft exceptions to the prohibition on the use or threat of force. Those who place greater value on sovereignty (and, they would argue, democratic rule of law), have rejected any humanitarian intervention not authorized by the Security Council as illegal and on occasion have portrayed the human rights movement as “anti-sovereigntist” and even “antidemocratic.” In this Article, we offer another way forward— one that aims to respect sovereign rights while helping states meet their sovereign responsibilities and thereby alleviate the tension between the twin commitments of the modern international legal system. Rather than seek to craft an exception to state sovereignty to meet humanitarian aims, we argue for empowering states to meet their sovereign responsibility through what we call “consent-based intervention.
Achieving a quantum smart workforce
Interest in building dedicated Quantum Information Science and Engineering
(QISE) education programs has greatly expanded in recent years. These programs
are inherently convergent, complex, often resource intensive and likely require
collaboration with a broad variety of stakeholders. In order to address this
combination of challenges, we have captured ideas from many members in the
community. This manuscript not only addresses policy makers and funding
agencies (both public and private and from the regional to the international
level) but also contains needs identified by industry leaders and discusses the
difficulties inherent in creating an inclusive QISE curriculum. We report on
the status of eighteen post-secondary education programs in QISE and provide
guidance for building new programs. Lastly, we encourage the development of a
comprehensive strategic plan for quantum education and workforce development as
a means to make the most of the ongoing substantial investments being made in
QISE.Comment: 18 pages, 2 figures, 1 tabl
Recommended from our members
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.
In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978.
Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90.
Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19.
US National Institutes of Health and Operation Warp Spee